Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 65 for “"Phase II Clinical Trials"”.

  1. Adaptive designs in phase II clinical trials

    Clinical trials play a very important role in the development process of new therapies. Recently there has been a rapid increase in the research and creation of new modern molecular agents, which makes necessary the development of more flexible and adaptive designs for the implementation of …

    greece Repository record for Adaptive designs in phase II clinical trials (opens in a new tab)

  2. Adaptive designs for phase II clinical trials with binary endpoints.

    … of Simon (1989) two different levels of clinical significance are assumed for each experimental design. There are two problems with original design that are addressed. The first problem is that no explicit stopping boundary for efficacy was provided in the early stages. The other problem …

    baylor Repository record for Adaptive designs for phase II clinical trials with binary endpoints. (opens in a new tab)

  3. Innovative Methods for the Design and Analysis of Phase II Clinical Trials

    … There is significant potential for improving clinical trial designs, particularly for phase II trials, which play a critical role in the drug development process. Innovative methods are especially necessary for addressing key challenges in phase II trials in terms of dose-ranging study, …

    uthsc Repository record for Innovative Methods for the Design and Analysis of Phase II Clinical Trials (opens in a new tab)

  4. EARLY TERMINATION IN PHASE II CLINICAL TRIALS: ADMISSIBLE DESIGNS USING DECREASINGLY INFORMATIVE PRIORS

    In Phase II clinical trials, Thall and Simon’s Bayesian posterior probability design is commonly implemented to allow for an early termination to determine whether a new treatment warrants further investigation in a larger-scale Phase III trial; this in turn requires a pre-selected prior …

    vcu Repository record for EARLY TERMINATION IN PHASE II CLINICAL TRIALS: ADMISSIBLE DESIGNS USING DECREASINGLY INFORMATIVE PRIORS (opens in a new tab)

  5. Bayesian Adaptive Designs for Phase II Clinical Trials Evaluating Subgroup-Specific Treatment Effect

    In Phase II clinical trials, particularly for molecularly targeted agents (MTAs) and biotherapies, there is a critical need to evaluate subgroup-specific treatment effects due to the heterogeneous nature of these therapies. This dissertation introduces two innovative Bayesian adaptive designs for …

    iupui Repository record for Bayesian Adaptive Designs for Phase II Clinical Trials Evaluating Subgroup-Specific Treatment Effect (opens in a new tab)

  6. On Simon’s two-stage design for Phase II clinical trials: extension and improvements

    Το Simon two stage design υπήρξε εξαιρετιϰά επιδραστιϰό στον σχεδιασμό ϰλινιϰών δοϰιμών Φάσης ΙΙ. Πρόϰειται για έναν προσαρμοστιϰό σχεδιασμό στον οποίο οι α- σϑενείς εντάσσονται στη δοϰιμή σε στάδια, ώστε η δοϰιμή να μπορεί να διαϰοπεί νωρίτερα εάν τα μέχρι τότε αποτελέσματα δεν είναι ενϑαρρυντιϰά. …

    athens Repository record for On Simon’s two-stage design for Phase II clinical trials: extension and improvements (opens in a new tab)

  7. Optimal Designs for Two-Arm Randomized Phase II Clinical Trials with Multiple Constraints

    Properly planned and executed clinical trials play a vital role for modern medicine. They have been considered as the most important studies for the development of novel treatments. In particular, designs for phase II clinical trials are crucial for new treatments development and assessment since …

    ku Repository record for Optimal Designs for Two-Arm Randomized Phase II Clinical Trials with Multiple Constraints (opens in a new tab)

  8. Sample size, error rates and effects of prior-misspecifications in phase II clinical trials

    … important developments in statistical designs in phase II clinical trials. Those designs either optimize the expected sample size or the total number of sample size, under the constraints of some system error rates. This thesis briefly discusses the relationship among the error rates and provides …

    nus Repository record for Sample size, error rates and effects of prior-misspecifications in phase II clinical trials (opens in a new tab) Download file for Sample size, error rates and effects of prior-misspecifications in phase II clinical trials (opens in a new tab)

  9. A Single-Arm Multi-Stage Design & A Flexible Pick-the-Winner Design for Phase II Clinical Trials

    Phase 2 clinical trials are designed to evaluate the efficacy and safety of potential new therapies, treatment regimens, and other interventions. The majority of phase 2 trial designs were based on frequentist statistical approaches [1] before the 1980s, after which Bayesian approaches have been …

    ku Repository record for A Single-Arm Multi-Stage Design & A Flexible Pick-the-Winner Design for Phase II Clinical Trials (opens in a new tab)

  10. Statistical Inferences of Two-Stage Phase II Cancer Clinical Trials with Two Co-primary Endpoints

    … used to assess the effect of a new agent in phase II clinical trials. The optimal two-stage designs with two co-primary endpoints have been proposed to assess the effects of new cancer treatments, such as cytostatic or molecularly targeted agents (MTAs), based on both response rate and early …

    queens Repository record for Statistical Inferences of Two-Stage Phase II Cancer Clinical Trials with Two Co-primary Endpoints (opens in a new tab)

  11. Total synthesis of spiruchostatin A and structural analogues

    … agents, and examples have now advanced to phase II clinical trials. The total synthesis of spiruchostatin A and the structural analogues was accomplished. This work unambiguously confirms the structure of spiruchostatin A. Biological testing shows spiruchostatin A to be a potent HDAC …

    soton Download PDF for Total synthesis of spiruchostatin A and structural analogues (opens in a new tab)

  12. Statistical design of phase I clinical trials

    My MSc thesis is focused on parametric designs of Phase I clinical trials, using the continual reassessment method. A parametric model with unknown parameters is assumed. The observations are either toxic or nontoxic. Observations of toxicities are used to update the posterior distribution. Dose …

    manitoba Repository record for Statistical design of phase I clinical trials (opens in a new tab)

  13. Characterising the role of AMIGO3 in oligodendrocytes and demyelinating diseases

    … therapies for demyelinating diseases. Recent trials aimed at the leucine rich repeat (LRR) protein, LINGO1 to encourage remyelination have shown promising preclinical data however phase II clinical trials have been unsuccessful. The analogous LRR protein, AMIGO3 is predicted to overcome LINGO1 …

    birmingham Download PDF for Characterising the role of AMIGO3 in oligodendrocytes and demyelinating diseases (opens in a new tab)

  14. Synthesis of exo-affinity labeling agents of protein tyrosine phosphatase non-receptor type 1

    … with no success. Only one drug is currently in phase II clinical trials. We have developed a synthetic protocol to create a library of molecules that target residues outside the active site and covalently bind to the enzyme via close proximity alkylation. These molecules will be analyzed towards …

    missouri Repository record for Synthesis of exo-affinity labeling agents of protein tyrosine phosphatase non-receptor type 1 (opens in a new tab)

  15. Production and Testing of a Novel Live-Attenuated Chikungunya Vaccine

    … to the 181/25 vaccine, which progressed to phase II clinical trials.

    utmb Repository record for Production and Testing of a Novel Live-Attenuated Chikungunya Vaccine (opens in a new tab)

  16. Targeting CDK to Prevent and Treat Retinoblastoma and other Cancers

    … like CDK inhibitors, have failed to pass Phase II clinical trials. Since expansion of premalignant cells is critical for tumor establishment, we wondered whether CDK inhibitors would be more effective in prevention than treatment. To examine this, we leveraged pharmaceutical and genetic …

    toronto-retro Repository record for Targeting CDK to Prevent and Treat Retinoblastoma and other Cancers (opens in a new tab)

  17. A phase II two stage clinical trial design to handle latent heterogeneity for a binary response.

    Phase II clinical trial are generally single arm trial where a homogeneity assumption is placed on the response. In practice, this assumption may be violated resulting in a heterogeneous response. This heterogeneous or overdispersed response can be decomposed into distinct subgroups based on the …

    louisville Repository record for A phase II two stage clinical trial design to handle latent heterogeneity for a binary response. (opens in a new tab)

  18. Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy

    … using a phenotypic screen, progressed to Phase II clinical trials in DMD patients. Interim 24-week data demonstrated reduced muscle fibre damage and increased levels of utrophin, providing the first evidence of ezutromid target engagement and proof of mechanism. However, these effects were …

    oxford Repository record for Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy (opens in a new tab)

  19. Exact Tests and Designs in Drug Development and Evaluation of Medical Devices

    … the evaluation of drugs and medical devices. In Phase II clinical trials of drug development, establishing the dose-response relationship is crucial for identifying the optimal dose for use in Phase III. The Multiple Comparison Procedure–Modeling (MCP-Mod) method is developed for this purpose, …

    buffalo Repository record for Exact Tests and Designs in Drug Development and Evaluation of Medical Devices (opens in a new tab)

Page 1 of 4